Induction of Adherent Activity in Mastocytoma P-815 Cells by the Cooperation of Two Prostaglandin E2 Receptor Subtypes, EP3 and EP4*

Noriyuki Hatae, Ayumi Kita, Satoshi Tanaka, Yukihiko Sugimoto, and Atsushi IchikawaDagger

From the Department of Physiological Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida, Sakyo-ku, Kyoto 606, Japan

Received for publication, February 6, 2003, and in revised form, March 7, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we investigated the role of PGE2 in mouse mastocytoma P-815 cell adhesion to extracellular matrix proteins (ECMs) in vitro. We report that PGE2 accelerated ProNectin FTM (a proteolytic fragment of fibronectin)-mediated adhesion, which was abolished by addition of the GRGDS peptide, an inhibitor of the RDG binding site of ProNectin FTM. We show that the cAMP level and cAMP-regulated protein kinase (PKA) activity are critical mediators of this PGE2 effect, because the cell-permeable cAMP analogue 8-Br-cAMP accelerated P-815 cell adhesion to ProNectin FTM and the pharmacological inhibitor of PKA, H-89, blocked PGE2-mediated adhesion. Consistent with mRNA expression of the Gs-coupled EP4- and Gi-coupled EP3-PGE receptor subtypes, P-815 cell adhesion was accelerated by treatment with a selective EP4 agonist, ONO-AE1-329, but not a selective EP1/EP3 agonist, sulprostone. However, simultaneous treatment with ONO-AE1-329 and sulprostone resulted in augmentation of both the cAMP level and cell adhesion. The augmentation of EP3-mediated cAMP synthesis was dose-dependent, without affecting the half-maximal concentration for EP4-mediated Gs-activity, which was inhibited by a Gi inhibitor, pertussis toxin. In conclusion, these findings suggest that PGE2 accelerates RGD-dependent adhesion via cooperative activation between EP3 and EP4 and contributes to the recruitment of mast cells to the ECM during inflammation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Differentiated mast cells (MCs),1 which originate from bone marrow stem cells, traffic throughout the circulation and adhere to the extracellular matrix (ECM) in various tissues. MCs are widely distributed in tissues throughout the body, especially in connective tissues, serosal cavities, and on mucosal surfaces under normal physiological conditions. This characteristic distinguishes MCs from other bone marrow-derived hematopoietic cells, such as basophils, neutrophils, and eosinophils. MCs congregate around nerves, blood vessels, and lymphatic vessels. MCs therefore interact with not only the ECM but with other cells as well. As well known for rodent connective tissue-typed MCs and mucosal-typed MCs, the biological activity of MCs vary with their interactions with the ECM and other cells.

MCs are widely distributed along basement membranes, indicating that MCs might adhere to laminin. Supporting this fact, mouse bone marrow-derived mast cells (BMMC) have been reported to adhere to laminin, when the cells were activated by phorbol 12-myristate 13-acetate (PMA) (1-3) or antigen-stimulated aggregation of Fcepsilon RI (4). In addition to laminin, MCs can adhere to other matrix components such as fibronectin (5) and vitronectin (6, 7). As with laminin, the adherence of BMMC to fibronectin has been reported to occur through activation with PMA or after aggregation of Fcepsilon RI. These adherence activities required calcium (3). In contrast to BMMC, the mouse PT18 cell line spontaneously adhered to laminin (1), and human skin mast cells also spontaneously adhered to laminin and fibronectin (8). These previous findings indicate that the interactions between MCs and matrix components may depend on the cells involved and the kinds of stimuli.

PGE2, which is involved in inflammation section (9), affects both differentiation and growth of MCs in vitro. PGE2 enhances mast cell differentiation from cord blood mononuclear cells (10) and in the fibroblast co-culture system (11). Very recently, Dormond et al. (12) reported that a COX-2 inhibitor suppressed alpha Vbeta 3-dependent HUVEC spreading, migration, and angiogenesis through Rac activation (12), and PGE2 accelerated alpha Vbeta 3-mediated HUVEC responses in a cAMP-dependent manner (13). However, no reports have published the effects of PGE2 on MC adhesion to the ECM.

The PGE2 receptors (EP) are comprised of four subtypes, EP1, EP2, EP3, and EP4, which are coupled to different G proteins and signal pathways (14, 15). Among these subtypes, EP2 and EP4 couple to Gs, resulting in increases of intracellular cAMP concentrations (16, 17), while EP3 couples to Gi, causing a decrease in cAMP levels (18-21). Very recently, we and other investigators have reported that activation of the Gi-coupled EP3 receptor was able to augment adenylyl cyclase activity via stimulation of a Gs-coupled receptor (22, 23). We previously reported that the mouse EP3beta receptor was able to augment EP2-induced adenylyl cyclase activity in both EP2- and EP3-transfected COS-7 cells (22). Southall and Vasko (23) showed that the simultaneous depletion of rat EP3C and EP4 was essential to abolish PGE2-stimulated cAMP production and neuropeptide release in rat sensory neurons (23). These permissive actions between the two subtypes may be involved in the events of a number of physiological actions of PGE2 (15).

Here we extended the analyses of the effects of PGE2 on adhesion of mouse mastocytoma P-815 cells to the fibronectin component in a PKA-dependent manner, and we examined the correlation between cAMP levels and adhesion in P-815 cells to see whether EP3 could augment EP4-induced cAMP synthesis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Sulprostone was a generous gift from Dr. M. P. L. Caton of Rhone-Poulenc Ltd. ONO-AE1-259 and ONO-AE1-329 were generous gifts from ONO Pharmaceuticals (Osaka, Japan). ProNectin FTM (Pronectin-F) and ProNectin LTM (Pronectin-L) were generous gifts from Sanyo Chemical Industries, Ltd. (Kyoto, Japan). The GRGDS peptide was obtained from the PEPTIDE Institute (Osaka, Japan). Collagen I-coated plates were from BD PharMingen Labware, the 125I-labeled cAMP assay system from Amersham Biosciences. Pertussis toxin (PT) from Seikagaku Kogyo (Tokyo, Japan), [5,6,8,11,12,14,15-3H]PGE2 (164 Ci/mmol) from Amersham Biosciences and PGE2 from Cayman Chemical (Ann Arbor, MI). Rabbit polyclonal anti-A cyclase II (C-20) antibody, rabbit polyclonal anti-A cyclase IV (C-20) antibody, and goat polyclonal anti-A cyclase VII (M-20) antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).

Reverse Transcription-Polymerase Chain Reaction-- Mouse mastocytoma P-815 cells (P-815 cells) were maintained in Fischer's medium with 10% fetal bovine serum under humidified air containing 5% CO2 at 37 °C. Total RNA was isolated from P-815 cells using Isogen (Nippon Gene) according to the manufacturer's instructions. The reverse transcription (RT) reaction was performed using Molony murine leukemia virus reverse transcriptase (Invitrogen) in the presence of random hexamers. The polymerase chain reaction (PCR) was performed with Taq DNA polymerase (TOYOBO) using the first strand template. The primers were designed to be selective for the prostanoid receptors, and the sequences used were as follows: EP1 (base pairs (545 bp)), 5'-GCC ACT GAT CCA CGC GGC GCG CGT ATC TGT GGC C-3' (forward) and 5'-CGA TGG CCA ACA CCA CCA ACA CCA GCA GGG-3' (reverse); EP2 (604 bp), 5'-TTC ATA TTC AAG AAA CCA GAC CCT GGT GGC-3' (forward) and 5'-AGG GAA GAG GTT TCA TCC ATG TAG GCA AAG-3' (reverse); EP3 (608 bp), 5'-ATC CTC GTG TAC CTG TCA CAG CGA CGC TGG-3' (forward) and 5'-TGC TCA ACC GAC ATC TGA TTG AAG ATC ATT-3' (reverse); EP4 (601 bp), 5'-GAC TGG ACC ACC AAC GTA ACG GCC TAC GCC-3' (forward) and 5'-ATG TCC TCC GAC TCT CTG AGC AGT GCT GGG-3' (reverse); IP (602 bp), 5'-CCT GCA GTG TTT GTG GCC TAT GCT CGA AAC-3' (forward) and 5'-CTG CTG TCT GGG GCG ATG GCC TGA GTG AAG-3' (reverse); DP (604 bp), 5'-AAA GGA ACT GCT GCC TGC CTC AGG CAA TCA-3' (forward) and 5'-GTT CTC AAG TTT AAA GGC TCC ATA GTA CGC-3' (reverse); FP (603 bp), 5'-GCA TAG CTG TCT TTG TAT ATG CTT CTG ATA-3' (forward) and 5'-GTG TCG TTT CAC AGG TCA CTG GGG AAT TAT-3' (reverse); TP (607 bp), 5'-TGC CTT GTT GGA CTG GCG AGC CAC TGA CCC-3' (forward) and 5'-CAG GTA GAT GAG CAG CTG GTG CTC TGT GGC-3' (reverse). The thermal cycle programs used were as follows: EP1, 94 °C for 1 min and then 94 °C for 1 min, 72 °C for 3.5 min for the first 10 cycles, 94 °C for 1 min, 69 °C for 2 min, 72 °C for 1.5 min for the next 10 cycles, 94 °C for 1 min, 66 °C for 2 min, 72 °C for 1.5 min for the last 15 cycles, followed by 72 °C for 7 min; EP2, EP3, EP4 and DP, 94 °C for 1 min and then 30 cycles of 94 °C for 0.8 min, 60 °C for 0.7 min, 72 °C for 1.5 min, followed by 72 °C for 7 min; IP, 94 °C for 1 min and then 30 cycles of 94 °C for 0.8 min, 65 °C for 0.7 min, 72 °C for 1.5 min, followed by 72 °C for 7 min; FP and TP, 94 °C for 1 min and then 94 °C for 1 min, 72 °C for 3.5 min for the first 10 cycles, 94 °C for 1 min, 67 °C for 2 min, 72 °C for 1.5 min for the next 10 cycles, 94 °C for 1 min, 63 °C for 2 min, 72 °C for 1.5 min for the last 15 cycles, followed by 72 °C for 7 min. Samples were visualized on a 1.5% agarose gel.

[3H]PGE2 Binding Assay-- P-815 cells were homogenized with a Potter-Elvehjem homogenizer in 20 mM Tris-HCl (pH 7.5), containing 10 mM MgCl2, 1 mM EDTA, 20 µM indomethacin, and 0.2 mM phenylmethylsulfonyl fluoride. After centrifugation at 250,000 × g for 20 min, the pellet (membrane fraction) was washed, suspended in 10 mM Mes-NaOH (pH 6.0) containing 10 mM MgCl2, and 1 mM EDTA, and was used for the [3H]PGE2 binding assay. The membrane fraction (50 µg) was incubated with 4 nM [3H]PGE2 at 30 °C for 1 h, and [3H]PGE2 binding to the membrane fraction was determined as described previously (24). Nonspecific binding was determined using a 2,500-fold excess of unlabeled PGE2 in the incubation mixture.

Measurement of cAMP Formation-- Cyclic AMP levels in P-815 cells were determined as reported previously (25). P-815 cells (2 × 106 cells/assay) were suspended with 10 µM indomethacin in HEPES-buffered saline containing 140 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 1.2 mM MgCl2, 1.2 mM KH2PO4, 11 mM glucose, and 15 mM HEPES (pH 7.4), and preincubated for 10 min at 37 °C. Reactions were started by addition of test agents along with 500 µM 3-isobutyl-1-methyl-xanthine (Sigma). After incubation for 10 min at 37 °C, reactions were terminated by the addition of 10% trichloroacetic acid. The level of cAMP was measured by radioimmunoassay with an Amersham Biosciences cAMP assay system.

Expression of the Adenylyl Cyclase Subtypes-- Expression of adenylyl cyclase II, IV, and VII were determined by immunoblot analysis of whole cell detergent lysates of P-815 cells using rabbit polyclonal anti-A cyclase II (C-20) antibody, rabbit polyclonal anti-A-cyclase IV (C-20) antibody, and goat polyclonal anti-A cyclase (M-20) antibody. P-815 cells (2 × 108 cells) were washed twice in PBS. The cell pellet was suspended in 1 ml of radioimmune precipitation assay buffer containing 30 mM HEPES-NaOH (pH 7.3), 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, and 0.1% SDS, and incubated for 2 h at 4 °C. For protection against proteolytic degradation, a mixture of protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 100 µM benzamidine, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml E-64, and 1 µg/ml pepstatin A) was added. The mixture was then centrifuged at 10,000 × g for 15 min at 4 °C. The resulting supernatant was dissolved in Laemmli buffer and heated for 30 min at 60 °C. Aliquots (500 µg of protein) were then subjected to SDS-PAGE (7.5%) as described by Laemmli (26), and the separated proteins were transferred electrophoretically onto a polyvinylidene difluoride membrane in 25 mM Tris base containing 40 mM 6-aminohexanoic acid, 0.02% SDS, and 20% methanol at room temperature for 30 min at 15 V. The membrane fraction was rinsed in Tris-buffered saline (TBS) containing 20 mM Tris-HCl (pH 7.5) and 150 mM NaCl, and then preincubated overnight in TBS containing 5% nonfat milk at 4 °C. The membrane fraction was then incubated with anti-A cyclase antibodies (A cyclase II, IV, 1:200; A cyclase VII, 1:100) in TBS containing 5% nonfat milk for 1 h at 37 °C. After washing three times with TTBS (TBS containing 0.05% Tween 20) at room temperature, the membrane fraction was incubated with peroxidase-conjugated anti-rabbit or -goat IgG in TTBS for 1 h at room temperature, and then detected with the ECL Western blot detection reagent.

Cell Adhesion Assay-- P-815 cells were suspended in Fischer's medium with test agents along with 10% fetal bovine serum and 10 µM indomethacin at a density of 5 × 105 cells per ml, and 1 ml per well was dispensed into 12-well tissue culture plates. The 12-well tissue culture plates were precoated with 10 µg/ml of Pronectin-F or Pronectin-L for 5 min at room temperature. Nonspecific binding was determined by using wells precoated with bovine serum albumin (3%) for 1 h at room temperature. The P-815 cells were incubated for 8 h at 37 °C in a CO2-humidified atmosphere and non-adherent P-815 cells were suspended in 2 ml of PBS (non-adherent cells). The adherent P-815 cells were treated with PBS containing 0.02% EDTA and 0.25% trypsin at 37 °C for 30 min, and the collected cells were suspended in 2 ml of PBS containing 0.02% EDTA and 2% fetal bovine serum (adherent cells). The numbers of non-adherent and adherent cells were counted using the COULTER Z1 cell counter (Beckman Coulter). The percentage of cell adhesion was calculated with the following formula shown in Equation 1.


<UP>% cell adhesion = adherent cell number</UP> (Eq. 1)

<UP>× 100/</UP>(<UP>adherent cell number + non-adherent cell number</UP>)


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

P-815 Cell Adhesion to Pronectin-F-coated Plates-- When P-815 cells were cultured in Fischer's medium containing 10% fetal bovine serum together with 10 µM indomethacin, almost no attachment to non-coated plates was observed. However, after incubation with 1 µM PGE2 for 8 h, ~11% of P-815 cells were retained on the non-coated plates as adhered cells, after being washed three times with PBS containing 0.02% EDTA (Fig. 1A). We next examined the effect of fibronectin on cell adhesion using Pronectin-F, which consists of multiple copies of the RGD cell attachment ligand of fibronectin (27). The number of adhered P-815 cells did not significantly change between the Pronectin-F-coated plates and the non-coated plates when the cells were incubated without PGE2, but markedly increased upon incubation with 1 µM PGE2 (Fig. 1B). PGE2-induced adherent activity to Pronectin-F-coated plates almost completely disappeared with addition of the GRGDS peptide (Fig. 1C), which is a soluble inhibitor for the RDG site of fibronectin as well as Pronectin-F (28). Furthermore, this PGE2-treated cell adhesion was not affected by further incubation with 0.02% EDTA for 30 min, but the cells could be detached by 0.25% trypsin treatment.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Adhesion of PGE2-stimulated P-815 cells to Pronectin-F-coated plates. A, P-815 cells were incubated at 37 °C for 8 h with or without 1 µM PGE2. B, P-815 cells were incubated at 37 °C for 8 h in wells coated with or without Pronectin-F (10 µg/ml) in the presence (solid bars) or absence (open bars) of 1 µM PGE2, and the percentages of P-815 cell adhesion were determined as described under "Experimental Procedures." Values are shown as the means ± S.E. of triplicate experiments. *, p < 0.01 versus non-coat. C, P-815 cells were incubated at 37 °C for 8 h in wells coated with Pronectin-F (10 µg/ml) in the presence (closed circles) or absence (open circles) of 1 µM PGE2 together with the indicated concentrations of soluble GRGDS peptide, and the percentages of P-815 cell adhesion were determined as described under "Experimental Procedures." Values are means ± S.E. for triplicate experiments. *, p < 0.01 versus without the GRGDS peptide.

Expression of the EP3 and EP4 Subtypes in P-815 Cells-- The RT-PCR experiment revealed that P-815 cells express mRNAs for EP3, EP4, and IP (Fig. 2A). We confirmed the expression of the EP3 and EP4 receptor proteins by the replacement of the binding of 4 nM [3H]PGE2 to membrane fractions with 10 µM PGE2, sulprostone (EP1 and EP3 agonist), or ONO-AE1-329 (EP4 agonist). The order of replacement potency was found to be PGE2 > sulprostone > ONO-AE1-329 (Fig. 2B). These results indicate that PGE2 can bind to EP3 and EP4 present in the membrane fractions of P-815 cells.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 2.   Detection of prostaglandin receptor mRNAs and prostaglandin E2 receptor subtype proteins in P-815 cells. A, expression of mRNAs for the prostanoid receptors was assessed by RT-PCR. Total RNA from P-815 cells was isolated and subjected to RT-PCR, and PCR products for the EP1, EP2, EP3, EP4, IP, DP, FP, and TP receptors were detected according to the procedures described under "Experimental Procedures." B, expression of the EP subtypes, EP3 and EP4, was assessed by [3H]PGE2 binding to each subtype. The membranes of P-815 cells were incubated at 30 °C for 1 h with 4 nM [3H]PGE2 in the presence or absence (none) of 10 µM PGE2, 0.1 µM sulprostone (EP1, 3 agonist), 0.1 µM ONO-AE1-329 (EP4 agonist). Values are the means ± S.E. for triplicate determinations.

PGE2-induced cAMP and Protein Kinase A-dependent P-815 Cell Adhesion-- Along with PGE2, 8-Br-cAMP, and IBMX accelerated the adhesion of P-815 cells to Pronectin-F-coated plates (Fig. 3A). PGE2-mediated cell adhesion was greatly reduced by pretreatment with 10 µM H-89, a PKA inhibitor (Fig. 3B). On the other hand, phorbol 12-myristate 13-acetate (PMA) had no effect on cell adhesion in the absence of PGE2, and in addition, PGE2 did not change the intracellular Ca2+ level (data not shown). These results suggest that the PGE2-induced adhesion of P-815 cells to Pronectin-F is via a cAMP-dependent and cAMP-protein kinase A-dependent pathway.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 3.   Adhesion of PGE2-stimulated P-815 cells to Pronectin-F-coated wells mediated by PKA activation. A, P-815 cells were incubated at 37 °C for 8 h in wells coated with Pronectin-F (10 µg/ml) in the presence of 1 µM PGE2, 1 mM 8Br-cAMP, or 0.5 mM IBMX, and the percentages of P-815 cell adhesion were determined as described under "Experimental Procedures." Values are shown as the means ± S.E. for triplicate experiments. *, p < 0.01 versus untreated. B, P-815 cells were preloaded with or without 10 µM H-89 for 30 min, then the cells were incubated for 8 h in the presence or absence of 1 µM PGE2, with or without 10 µM H-89. The percentages of P-815 cell adhesion were determined as described under "Experimental Procedures." Values are shown as the means ± S.E. for triplicate experiments. *, p < 0.01 versus without H-89 treatment.

Sulprostone-induced Augmentation of ONO-AE1-329-induced cAMP Formation in P-815 Cells-- Since P-815 cells express the Gi-coupled EP3 as well as the Gs-coupled EP4, it is possible that PGE2 may bind to both subtype receptors at the same time, and hence the cAMP level may reflect the difference between Gs- and Gi-activated adenylyl cyclase activity. We therefore examined the cAMP levels in P-815 cells when treated with the EP1/EP3 agonist sulprostone and/or the EP4 agonist ONO AE1-329 (Fig. 4A). The cAMP level was increased by treatment with ONO-AE1-329 and reached a plateau level at 0.1 µM. However, cAMP accumulation induced by various concentrations of the EP4 agonist were all augmented by the simultaneous addition of sulprostone (1 µM), without affecting the half-maximal concentration, although sulprostone alone did not stimulate cAMP accumulation (Fig. 4A). The half-maximal concentration of sulprostone for EP3-mediated augmentation in EP4-induced cAMP synthesis was calculated to be ~5 × 10-8 M (data not shown). Furthermore, sulprostone-induced augmentation of ONO-AE1-329-activated cAMP formation was absolutely inhibited by treatment with PT, and the cAMP level was almost equal to that observed in the cells stimulated by ONO-AE1-329 alone (Fig. 4B). These findings suggest that EP3-mediated augmentation of Gs activity is achieved through Gbeta gamma subunits resulting from Gi/o protein activation (29), although EP4-mediated Gs activity is not.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Sulprostone-induced augmentation of ONO-AE1-329-stimulated cAMP formation in P-815 cells. A, P-815 cells were incubated at 37 °C for 10 min with 1 µM sulprostone in the presence of indicated concentrations of ONO-AE1-329. cAMP formation was determined as described under "Experimental Procedures." Values are the means ± S.E. of triplicate experiments. *, p < 0.01 versus stimulation with the indicated concentrations of ONO-AE1-329 alone. B, P-815 cells were pretreated with 25 ng/ml PT for 7 h, and the treated cells were then incubated at 37 °C for 10 min with 1 µM PGE2, 1 µM sulprostone, 1 µM ONO-AE1-329, or both 1 µM sulprostone and 1 µM ONO-AE1-329, and cAMP formation was determined as described under "Experimental Procedures." Values are shown as the means ± S.E. for triplicate experiments. *, p < 0.01 versus without PT treatment.

Sulprostone-induced Augmentation of ONO-AE1-329-stimulated P-815 Cell Adhesion to Pronectin-F-- We next examined whether EP3 stimulation could augment EP4-mediated adhesion of P-815 cells to Pronectin-F. 1 µM sulprostone further augmented ONO-AE1-329 induced P-815 cell adhesion to Pronectin-F (Fig. 5), and the level of EP3-mediated augmentation of this adhesion was almost equal to the level of cAMP augmentation by the EP3 subtype (Fig. 4B). These findings suggest that PGE2-stimulated P-815 cell adhesion to Pronectin-F is mediated through the cooperative action of the EP3 and EP4 subtypes.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of PGE2 on adhesion of P-815 cells to Pronectin-F-coated wells. P-815 cells were incubated at 37 °C for 8 h in wells coated with Pronectin-F (10 µg/ml) in the presence or absence of 1 µM PGE2, 1 µM sulprostone, 1 µM ONO-AE1-329, or both 1 µM sulprostone and 1 µM ONO-AE1-329. The percentages of P-815 cell adhesion were determined as described under "Experimental Procedures." Values are shown as the means ± S.E. for triplicate experiments. *, p < 0.01 versus stimulation with ONO-AE1-329 alone.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PGE2 was previously reported to affect both differentiation and growth of mast cells in vitro. For example, PGE2 is essential for the differentiation of IL-3-dependent mouse mast cells from spleen cells (30), PGE2 enhanced human mast cell differentiation from cord blood mononuclear cells by inhibiting the production of macrophage-derived GM-CSF (10), and PGE2 enhanced the growth of differentiated mast cells in a fibroblast co-culture system (11). It is therefore possible that PGE2 plays a role in the interaction of mast cells with fibroblastic cells and extracellular matrix components. The interaction between mast cells and extracellular matrix components have profound influences on the targeting of mast cell progenitors to specific locations, the distribution of mast cell subsets, and the biological responsiveness of mast cells in tissues. The ability of mast cells to adhere to fibronectin, which involves the RGD sequence located within the cell-attachment domain of the fibronectin molecule, may play a role in the migration of mast cells in various tissues (5). In the present report, we found that PGE2 is able to stimulate the adhesion of P-815 cells to Pronectin-F through the RGD cell attachment domain of fibronectin, and that this adherent activity is mediated via a cAMP-dependent pathway induced by the activation of the EP4 and/or EP3 receptors. It is possible that the cAMP-protein kinase A pathway may be involved in the induction of these cell attachment molecules, as PGE2-induced cell attachment was inhibited by treatment with H-89 (Fig. 3B) and cycloheximide (data not shown). However, neither PGE2 nor 8Br-cAMP augmented the expression of VLA-5, one of the fibronectin receptors (data not shown). Therefore, cycloheximide may affect the signaling pathway of the fibronectin receptors. Further experiments are required to clarify these points.

Prostaglandin E2 acts through binding to its specific receptors, which are comprised of four subtypes, EP1, EP2, EP3, and EP4 (14, 15). Among them, EP3 and EP4 couple to Gi and Gs, and result in inhibition and stimulation of adenylyl cyclase activity, respectively (17-21). The mouse EP3 receptor is comprised of three isoforms, EP3alpha , EP3beta , and EP3gamma , which differ in their C terminus. Among them, EP3beta , which was used in this experiment is known to be coupled to the Gi protein (19). Very recently, activation of a Gi-coupled receptor has been reported to augment the adenylyl cyclase activity induced by the stimulation of a Gs-coupled receptor in COS-7 cells. For example, activation of Gi-coupled receptors such as alpha 2 adrenoreceptor (29) and bradykinin B2 receptor (32) lead to the augmentation of Gs-stimulated adenylyl cyclase in COS-7 cells. This synergistic effect has not been clearly shown in mammalian cells. Southall and Vasko (23) showed that the simultaneous depletion of both rat EP3C and EP4 was essential for abolishing PGE2-stimulated cAMP production and neuropeptide release in rat sensory neurons (23). In the current experiment we showed that the Gi-coupled EP3 agonist sulprostone augmented cAMP formation induced by the EP4 agonist ONO-AE1-329 in P-815 cells. Similarly, we found that sulprostone was able to augment cAMP formation in P-815 cells activated by an IP agonist, carbacyclin, suggesting that the augmentative effects of EP3 can be observed irrespective of Gs activation. The mechanism underlying these phenomena was thought to be via Gbeta gamma -mediated activation of type IV adenylyl cyclase (29), because pretreatment with PT inhibited the augmentation by the activation of the Gi-coupled EP3 receptor, and P-815 cells express type IV adenylyl cyclase (data not shown). Therefore, Gbeta gamma -mediated activation of type IV adenylyl cyclase may be involved in EP3-mediated signaling to augment EP4-stimulated adenylyl cyclase activity in P-815 cells.

Although the involvement of phosphatidylinositol 3-kinase (PI3K) in cell adhesion to matrix proteins is shown in a variety of cell types (33), the role of PI3K in mast cell adhesion is still unknown. Kinashi et al. (31) reported that the adhesion of platelet-derived growth factor receptor-expressed bone marrow-derived mast cells was inhibited by the addition of the PI3K inhibitor wortmannin. To understand whether PI3K is activated by PGE2 during P-815 cell adhesion, we examined the effect of the PI3K inhibitors, wortmannin (100 nM) and LY294002 (10 µM) on EP3/EP4-agonist induced cell adhesion to fibronectin. As a result, these inhibitors showed an additive effect on the augmentation of PGE2-induced cell adhesion (wortmannin: 81.7 ± 0.1% and LY294002: 82.4 ± 0.2%, compared with PGE2 stimulation alone: 24.8 ± 0.6%). Furthermore, each inhibitor alone had an effect on cell adhesion (wortmannin: 20.4 ± 0.1% and LY294002: 24.1 ± 0.1%, compared with the absence of these inhibitors (3.3 ± 0.1%)). Therefore, these results indicate that P-815 cell attachment to fibronectin is regulated by two independent signaling pathways involving PKA and PI3K. Further experiments are necessary to clarify the fundamental differences in the signaling involving PKA and PI3K in P-815 cell attachment to fibronectin. In summary, this study clearly demonstrates that two subtypes of the PGE2 receptor, EP3 and EP4, are cooperatively involved in PGE2-evoked and cAMP-mediated functions of P-815 cell adhesion.

    ACKNOWLEDGEMENTS

We thank Dr. M. P. L. Caton of Rhone-Poulenc Ltd. for the generous gift of sulprostone. We are grateful to Dr. Manabu Negishi of the Laboratory of Molecular Neurobiology, Graduate School of Biostudies, University of Kyoto for valuable advice on this study.

    FOOTNOTES

* This work was supported in part by a grant-in-aid for Scientific Research by the Ministry of Education, Science, Sports, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Physiological Chemistry, Faculty of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606, Japan. Tel.: 81-75-753-4527; Fax: 81-75-753-4557; E-mail: aichikaw@pharm.kyoto-u.ac.jp.

Published, JBC Papers in Press, March 11, 2003, DOI 10.1074/jbc.M301312200

    ABBREVIATIONS

The abbreviations used are: MC, mast cell; PG, prostaglandin; G protein, heterotrimeric GTP-binding protein; PT, pertussis toxin; PMA, phorbol 12-myristate 13-acetate; PBS, phosphate-buffered saline; Mes, 4-morpholineethanesulfonic acid; PI3K, phosphatidylinositol 3-kinase; PKA, cAMP-dependent protein kinase; ECM, extracellular matrix.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Thompson, H. L., Burbelo, P. D., Segui-Real, B., Yamada, Y., and Metcalfe, D. D. (1989) J. Immunol. 143, 2323-2327[Abstract/Free Full Text]
2. Thompson, H. L., Burbelo, P. D., Yamada, Y., Kleiman, H. K., and Metcalfe, D. D. (1989) J. Immunol. 143, 4188-4192[Abstract/Free Full Text]
3. Thompson, H. L., Burbelo, P. D., Yamada, Y., Kleiman, H. K., and Metcalfe, D. D. (1991) Immunology 72, 144-149[Medline] [Order article via Infotrieve]
4. Thompson, H. L., Burbelo, P. D., and Metcalfe, D. D. (1990) J. Immunol. 145, 3425-3431[Abstract/Free Full Text]
5. Dastych, J., Costa, J. J., Thompson, H. L., and Metcalfe, D. D. (1991) Immunology 73, 478-484[Medline] [Order article via Infotrieve]
6. Bianchine, P. J., Burd, P. R., and Metcalfe, D. D. (1992) J. Immunol. 149, 3665-3671[Abstract/Free Full Text]
7. Gurish, M. F., Bell, A. F., Smith, T. J., Ducharme, L. A., Wang, R.-K., and Weis, J. H. (149) J. Immunol. 149, 1964-1972
8. Walsh, L. J., Kaminer, M. S., Lazarus, G. S., Lavker, R. M., and Murphy, G. F. (1991) Lab. Invest. 65, 433-439[Medline] [Order article via Infotrieve]
9. Ohuchi, K., Yoshino, S., Kanaoka, K., Tsurufuji, S., and Levine, L. (1982) Int. Archs. Allergy Appl. Immun. 68, 326-331
10. Saito, H., Ebisawa, M., Tachimoto, H., Shichijo, M., Fukagawa, K., Matsumoto, K., Iikura, Y., Awaji, T., Tsujimoto, G., Yanagida, M., Uzumaki, H., Takahashi, G., Tsuji, K., and Nakahata, T. (1996) J. Immunol. 157, 343-350[Abstract]
11. Kameyoshi, Y., Morita, E., Tanaka, T., Hiragun, T., and Yamamoto, S. (2000) Arch. Dermatol. Res. 292, 240-247[CrossRef][Medline] [Order article via Infotrieve]
12. Dormond, O., Foletti, A., Paroz, C., and Ruegg, C. (2001) Nat. Med. 7, 1041-1047[CrossRef][Medline] [Order article via Infotrieve]
13. Dormond, O., Bezzi, M., Mariotti, A., and Ruegg, C. (2002) J. Biol. Chem. 277, 45838-45846[Abstract/Free Full Text]
14. Coleman, R. A., Smith, W. L., and Narumiya, S. (1994) Pharmacol. Rev. 46, 205-229[Medline] [Order article via Infotrieve]
15. Narumiya, S., Sugimoto, Y., and Ushikubi, F. (1999) Physiol. Rev. 79, 1193-1226[Abstract/Free Full Text]
16. Katsuyama, M., Nishigaki, N., Sugimoto, Y., Morimoto, K., Negishi, M., Narumiya, S., and Ichikawa, A. (1995) FEBS Lett. 372, 151-156[CrossRef][Medline] [Order article via Infotrieve]
17. Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 7759-7762[Abstract/Free Full Text]
18. Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A., and Narumiya, S. (1992) J. Biol. Chem. 267, 6463-6466[Abstract/Free Full Text]
19. Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., Hirata, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 2712-2718[Abstract/Free Full Text]
20. Irie, A., Sugimoto, Y., Namba, T., Harazono, A., Honda, A., Watabe, A., Negishi, M., Narumiya, S., and Ichikawa, A. (1993) Eur. J. Biochem. 217, 313-318[Abstract]
21. Irie, A., Segi, E., Sugimoto, Y., Ichikawa, A., and Negishi, M. (1994) Biochem. Biophys. Res. Commun. 204, 303-309[CrossRef][Medline] [Order article via Infotrieve]
22. Hatae, N., Yamaoka, K., Sugimoto, Y., Negishi, M., and Ichikawa, A. (2002) Biochem. Biophys. Res. Commun. 290, 162-168[CrossRef][Medline] [Order article via Infotrieve]
23. Southall, M. D., and Vasko, M. R. (2001) J. Biol. Chem. 276, 16083-16091[Abstract/Free Full Text]
24. Negishi, M., Irie, A., Sugimoto, Y., Namba, T., and Ichikawa, A. (1995) J. Biol. Chem. 270, 16122-16127[Abstract/Free Full Text]
25. Negishi, M., Sugimoto, Y., Irie, A., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 9517-9521[Abstract/Free Full Text]
26. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
27. Anderson, J. P., Cappello, J., and Martin, C. (1994) Biopolymers 34, 1049-1057[Medline] [Order article via Infotrieve]
28. Akiyama, S. K., and Yamada, K. M. (1985) J. Biol. Chem. 260, 10402-10405[Abstract/Free Full Text]
29. Fereman, A. D., Conklin, B. R., Schrader, K. A., Reed, R. R., and Bourne, H. R. (1992) Nature 356, 159-161[CrossRef][Medline] [Order article via Infotrieve]
30. Hu, Z. Q., Asano, K., Seki, H., and Shimamura, T. (1995) J. Immunol. 155, 2134-2142[Abstract]
31. Kinashi, T., Escobedo, J. A., Williams, L. T., Takatsu, K., and Springer, T. A. (1995) Blood 86, 2086-2090[Abstract/Free Full Text]
32. Hanke, S., Nurnberg, B., Groll, D. H., and Liebmann, C. (2001) Mol. Cell. Biol. 21, 8452-8460[Abstract/Free Full Text]
33. Wu, C. (1999) J. Cell Sci. 112, 4485-4489[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.